RHEINBREITBACH, Germany (ots) - Jennewein Biotechnologie GmbH the leading manufacturer of human milk oligosaccharides (HMOs) in the world, announced today that the Intellectual Property Rights Branch, Regulations and Rulings, U.S. Customs and Border Protection issued a Ruling Letter which asserts that the HMO 2'-fucosyllactose (2'-FL) being produced by Jennewein ...
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a market leading and science-based company for developing and producing human milk oligosaccharides (HMOs) and rare monosaccharides, announced today that it has established its subsidiary in the USA. Jennewein Biotech USA Corporation, a Delaware Corporation, utilizing warehouses in Chicago, IL and Columbus, OH, will ...
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH today announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology. Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides ...
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH filed a patent infringement suit with the regional court in Mannheim on January 09, 2020 against Nestlé Nutrition GmbH and its holding company Nestlé Deutschland AG. Nestlé offers its infant formula Beba Supreme which contains two human milk oligosaccharides - ...
Rheinbreitbach (ots) - Jennewein Biotechnology announces another milestone in the Worldwide approval of a new product generation, the "HMO-Mix". The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats", was recently accepted for publication by the ...
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, Rheinbreitbach, the leading manufacturer of human milk oligosaccharides (HMOs), announces that the U.S. Food and Drug Administration (FDA) issued a "no question" response letter to Jennewein's supplement of its GRAS Notice GRN571, thereby acknowledging that the ...
Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...
Rheinbreitbach (ots) - On September 09, 2019, Administrative Law Judge Cameron Elliot of the US International Trade Commission issued an Initial Determination finding that one of the bacterial strains used by Jennewein Biotechnologie to make 2'-fucosyllactose (2'-FL) infringes a patent owned by Glycosyn LLC. In the ...
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and is a ...
Haifa, Israel and Miami (ots/PRNewswire) - INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MR-guided focused ultrasound (MRgFUS) announced today that the Neuravive focused ultrasound treatment will be a covered service for essential tremor patients in Israel. The ...
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours (CHU). This most recent legal ruling marks ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...
